BCAL Diagnostics Limited Profit Margin

The latest profit margin for BDX.AX is -515.83% as of June 2026. That compares with -256.24% in the prior-year period — down 101.3% year over year. That is below the sector sector average of 13.23%. Investors often review this figure alongside BCAL Diagnostics Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, BDX.AX's profit margin moved from -256.24% to -515.83% — a 101.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BCAL Diagnostics Limited's valuation or profitability profile.

Against its sector companies, BDX.AX currently prints -515.83% for profit margin, while the sector average sits near 13.23%. That is roughly 4000.0% below the sector mean. Large gaps often invite a closer look at BCAL Diagnostics Limited's growth, margins, and balance sheet.

Profit Margin shows how effectively BCAL Diagnostics Limited converts resources into returns. At -515.83%, BDX.AX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -256.24% in the prior-year period — down 101.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BDX.AX's profit margin (-515.83%), review year-over-year change from -256.24%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.